Latest news on Alzheimer's
Check out the latest news about Alzheimer's disease research that we carry out at the Barcelonaβeta Brain Research Center (BBRC). Discover the advances in Alzheimer's prevention in which our scientists participate, as well as the news of the Alfa Study, dedicated to the early detection and prevention of the disease.
José Luis Molinuevo has been named on the Highly Cited Researchers 2020 list
The scientific publications of the promoter of the BBRC Alzheimer's Prevention Program are among the 1% of the most cited in its field in Web of Science.
What are the differences according to race, ethnicity, sex and gender regarding Alzheimer's disease?
Dr. Eider M. Arenaza-Urquijo co-chairs an international working group that investigates the relationship of these aspects with resilience to the disease
The BBRC incorporates new members to its Scientific Advisory Board
The advisory board is composed of renowned researchers in the field of Alzheimer’s disease and neurodegenerative diseases
BBRC researchers identify new tau biomarkers to detect the preclinical phase of Alzheimer's disease
An international team of researchers, led at the BBRC, has discovered that a series of biomarkers recently described to detect the most advanced phase of Alzheimer's can also detect the preclinical phase of the disease in the cerebrospinal fluid and plasma.
The BBRC receives the European Commission award 'HR Excellence in Research'
The award recognizes the commitment of the research center with the principles set out in the European Charter for Researchers and the Code of Conduct for the Recruitment of research staff.
Avalanche of data against Alzheimer's
The digitization of the data collected in our studies allows us to accelerate our research, improve its integrity and make it available to researchers around the world.
Stance of the Pasqual Maragall Foundation on World Alzheimer's Day 2020
Discover #undíaparaolvidar
The FDA accepts license application for aducanumab, the first possible disease modifying drug for Alzheimer’s
Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.
Marc Suárez-Calvet is awarded an ERC Starting Grant to identify age-related blood factors as a therapeutic target for Alzheimer’s disease
The research, endowed with nearly 1.5 milion euros, will provide a new therapeutic target for Alzheimer's disease, in which age is the most important risk factor
